Genetic Technologies on Wednesday announced it is forming a strategic alliance with Qiagen to establish and develop a Centre of Excellence in Australia that will initially serve Australian and New Zealand markets.
Genetic Technologies said that the strategic alliance is expected to open commercial opportunities involving automation and increased capacity that supports long-term revenue growth.
The firm added that Qiagen will support the enhancement of its capabilities through software, hardware, consumable, and other technical solutions. Such solutions include reagents and Qiagen’s QCII software to enable completing next-generation sequencing (NGS)-related validation in house.
Further, Qiagen’s QIAseq targeted DNA Pro sample-to-insight solutions for NGS oncology and customized in-house data analysis tools are expected to provide sample-to-result services for Genetic Technologies customers.
Genetic Technologies said it expects the alliance with Qiagen will unlock the Australian reimbursable market for it in all testing categories, including for its geneType hereditary cancer test.